Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Mar;188(3):948-952.
doi: 10.1002/ajmg.a.62582. Epub 2021 Nov 25.

Leber congenital amaurosis as an initial manifestation in a Chinese patient with thiamine-responsive megaloblastic anemia syndrome

Affiliations
Case Reports

Leber congenital amaurosis as an initial manifestation in a Chinese patient with thiamine-responsive megaloblastic anemia syndrome

Shijing Wu et al. Am J Med Genet A. 2022 Mar.

Abstract

Thiamine-responsive megaloblastic anemia syndrome (TRMA) is an autosomal recessive disorder, inherited by the defective SLC19A2 gene that encodes a high-affinity thiamine transporter (THTR-1). TRMA is characterized by the occurrence of classical triad manifestations including megaloblastic anemia, diabetes mellitus, and sensorineural deafness. In addition to the systemic manifestations, ophthalmic features can be present and include retinitis pigmentosa, optic atrophy, cone-rod dystrophy, maculopathy, and Leber congenital amaurosis. Here we report a 6-year-old boy presenting severe early-onset retinal dystrophy with the initial diagnosis of Leber congenital amaurosis, which followed for 12 years. Diabetes mellitus occurred 3 years after vision problem. Eosinophilic granuloma of the left scapula was confirmed at 13 years old. Whole-exome sequencing was performed to identify two novel compound heterozygous variants c.725dupC (p.Ala243Serfs*3) and c.121G>A (p.Gly41Ser) in SLC19A2 gene (NM_006996.3). Oral thiamine supplementation treatment was initiated at 13 years. This case demonstrates Leber congenital amaurosis can present as the first clinical feature before systemic manifestations. Phenotypic variety should be aware and multidisciplinary teamwork and regular follow-up are important for TRMA patient care.

Keywords: Leber congenital amaurosis; SLC19A2 gene; thiamine-responsive megaloblastic anemia syndrome.

PubMed Disclaimer

Similar articles

References

REFERENCES

    1. Bergmann, A. K., Sahai, I., Falcone, J. F., Fleming, J., Bagg, A., Borgna-Pignati, C., Casey, R., Fabris, L., Hexner, E., Mathews, L., Ribeiro, M. L., Wierenga, K. J., & Neufeld, E. J. (2009). Thiamine-responsive megaloblastic anemia: Identification of novel compound heterozygotes and mutation update. The Journal of Pediatrics, 155, 888-892.e881.
    1. Brown, G. (2014). Defects of thiamine transport and metabolism. Journal of Inherited Metabolic Disease, 37, 577-585.
    1. Diaz, G. A., Banikazemi, M., Oishi, K., Desnick, R. J., & Gelb, B. D. (1999). Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nature Genetics, 22, 309-312.
    1. Fleming, J. C., Tartaglini, E., Steinkamp, M. P., Schorderet, D. F., Cohen, N., & Neufeld, E. J. (1999). The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nature Genetics, 22, 305-308.
    1. Habeb, A. M., Flanagan, S. E., Zulali, M. A., Abdullah, M. A., Pomahačová, R., Boyadzhiev, V., Colindres, L. E., Godoy, G. V., Vasanthi, T., Al Saif, R., Setoodeh, A., Haghighi, A., Haghighi, A., Shaalan, Y., Hattersley, A. T., Ellard, S., & De Franco, E. (2018). Pharmacogenomics in diabetes: Outcomes of thiamine therapy in TRMA syndrome. Diabetologia, 61, 1027-1036.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources